

# **CONTENTS**

|  |              |
|--|--------------|
| <b>CHAPTER 1 INTRODUCTION .....</b>  | <b>1-17</b>  |
| 1.1 Introduction.....  | 1            |
| 1.2 Objective of the Proposed Work.....  | 10           |
| 1.3 Hypothesis.....  | 11           |
| 1.4 Work Plan .....  | 11           |
| 1.5 References.....  | 12           |
| <br>   |              |
| <b>CHAPTER 2 LITERATURE REVIEW .....</b>   | <b>18-74</b> |
| 2.1 Human Immuno Deficiency Virus (HIV).....   | 18           |
| 2.1.1 Pathogenesis of HIV.....   | 18           |
| 2.1.2 HIV Reservoir sites .....  | 20           |
| 2.1.3 Treatment of HIV- HAART therapy .....  | 21           |
| 2.1.4 Protease Inhibitors (PIs) .....  | 22           |
| 2.2 Oral drug delivery .....   | 25           |
| 2.2.1 Physiological considerations in oral absorption across intestinal epithelium ..... | 27           |
| 2.2.2 Physicochemical considerations in the transport across intestinal epithelium.....  | 31           |
| 2.3 Solid lipid nanoparticles .....  | 33           |
| 2.3.1 Preparation techniques for SLNs .....  | 34           |
| 2.3.2 Composition of solid lipid nanoparticles.....                                      | 38           |
| 2.4 Nanoemulsion .....   | 41           |
| 2.4.1 Methods of preparation of Nanoemulsion.....  | 42           |
| 2.4.2 Composition of lipid nanoemulsion .....  | 44           |
| 2.5 Characterization of solid lipid nanoparticles and lipid nanoemulsion.....            | 47           |
| 2.5.1 Particle/ globule size .....   | 47           |
| 2.5.2 Polydispersibility index .....   | 48           |
| 2.5.3 Zeta potential .....   | 48           |
| 2.5.4 Shape and morphology .....   | 48           |

|   |               |
|---|---------------|
| 2.5.5 Crystallinity and polymorphism .....  | 49            |
| 2.5.6 Determination of incorporated drug .....  | 49            |
| 2.5.7 <i>In-vitro</i> assessment of drug release from nanoparticles and nanoemulsion .....        | 50            |
| 2.5.8 Short term stability of nanoemulsions .....   | 50            |
| 2.6 Bioavailability enhancement by SLNs and lipid nanoemulsion .....                              | 51            |
| 2.7 CD4 receptor targeting.....   | 53            |
| 2.8 Drug profiles .....   | 54            |
| 2.8.1 Darunavir .....   | 54            |
| 2.8.2 Atazanavir Sulfate .....  | 57            |
| 2.9 References.....   | 61            |
| <br>  |               |
| <b>CHAPTER 3 ANALYTICAL METHOD DEVELOPMENT.....</b>   | <b>75-120</b> |
| 3.1 Introduction.....   | 75            |
| 3.2 Materials .....   | 75            |
| 3.3 Methods for Darunavir estimation .....  | 76            |
| 3.3.1 UV spectroscopic method of Darunavir in methanol: DCM (7:3).....                            | 76            |
| 3.3.1.1 Preparation of calibration plot.....  | 76            |
| 3.3.1.2 Analytical method validation .....  | 76            |
| 3.3.2 Analytical interference study for Darunavir.....  | 77            |
| 3.3.3 UV spectroscopic method of Darunavir in simulated gastric fluid: methanol<br>(1:0.5).....   | 78            |
| 3.3.3.1 Preparation of simulated gastric fluid (SGF) .....  | 78            |
| 3.3.3.2 Preparation of calibration plot.....  | 78            |
| 3.3.4 UV spectroscopic method of Darunavir in simulated intestinal fluid:<br>methanol(1:0.5)..... | 78            |
| 3.3.4.1 Preparation of simulated intestinal fluid (SIF).....                                      | 78            |
| 3.3.4.2 Preparation of calibration plot.....  | 79            |
| 3.3.5 HPLC method development of Darunavir.....   | 79            |
| 3.3.5.1 Sample preparation.....   | 79            |
| 3.3.5.2 HPLC analysis .....   | 79            |
| 3.3.6 LCMS method for determination of Darunavir in plasma .....                                  | 80            |
| 3.3.6.1 Preparation of solutions.....   | 80            |
| 3.3.6.2 LCMS Analysis .....   | 80            |
| 3.3.7 LCMS method for determination of Darunavir in spleen .....                                  | 80            |

|  |                |
|--|----------------|
| 3.4 Methods for Atazanavir sulfate estimation .....                                  | 81             |
| 3.4.1 UV spectroscopic method of Atazanavir sulfate (ATZ) in methanol: DCM (7:3)     | 81             |
| 3.4.2 Analytical interference study for Atazanavir sulfate.....                      | 81             |
| 3.4.3 UV spectroscopic method of ATZ in simulated gastric fluid: methanol (1:0.5)... | 81             |
| 3.4.4 UV spectroscopic method of ATZ in simulated intestinal fluid: methanol (1:0.5) | 82             |
| 3.4.5 HPLC method development of Atazanavir sulfate.....                             | 82             |
| 3.4.5.1 Sample preparation.....  | 82             |
| 3.4.5.2 HPLC analysis .....  | 83             |
| 3.4.6 HPLC method for determination of Atazanavir sulfate in plasma.....             | 83             |
| 3.4.7 HPLC method for determination of Atazanavir sulfate in spleen .....            | 83             |
| 3.5 Results and discussion for methods of estimation of Darunavir.....               | 84             |
| 3.5.1 UV spectroscopic method of Darunavir in methanol: DCM (7:3).....               | 84             |
| 3.5.2 Analytical interference study for Darunavir.....                               | 87             |
| 3.5.3 UV method for estimation of Darunavir in SGF: methanol.....                    | 88             |
| 3.5.4 UV method for estimation of Darunavir in SIF: methanol .....                   | 91             |
| 3.5.5 HPLC method development of Darunavir.....                                      | 94             |
| 3.5.6 LCMS method for determination of Darunavir in plasma .....                     | 96             |
| 3.5.7 LCMS method for determination of Darunavir in spleen .....                     | 100            |
| 3.6 Results and discussion for methods of estimation of Atazanavir sulfate.....      | 102            |
| 3.6.1 UV spectroscopic method of Atazanavir sulfate in methanol: DCM (7:3).....      | 102            |
| 3.6.2 Analytical interference study for Atazanavir sulfate.....                      | 105            |
| 3.6.3 UV spectroscopic method of ATZ in SGF: methanol (1:0.5) .....                  | 106            |
| 3.6.4 UV spectroscopic method of ATZ in SIF: methanol (1:0.5).....                   | 109            |
| 3.6.5 HPLC method development of Atazanavir sulfate.....                             | 112            |
| 3.6.6 HPLC method for determination of Atazanavir sulfate in plasma.....             | 115            |
| 3.6.7 HPLC method for determination of Atazanavir sulfate in spleen .....            | 117            |
| 3.7 References.....  | 120            |
| <b>CHAPTER 4 FORMULATION DEVELOPMENT.....</b>  | <b>121-155</b> |
| 4.1 Introduction.....  | 121            |
| 4.2 Materials .....  | 122            |
| 4.3 Methods.....   | 123            |
| 4.3.1 Formulation development of Darunavir loaded solid lipid nanoparticles.....     | 123            |
| 4.3.1.1 Formulation of placebo (without drug) solid lipid nanoparticles.....         | 123            |

|   |   |                |
|---|---|----------------|
| 4.3.1.2                                 | Formulation of Darunavir loaded solid lipid nanoparticles.....  | 125            |
| 4.3.1.3                                 | Evaluation parameters .....   | 128            |
| 4.3.2                                   | Formulation development of peptide grafted SLN of Darunavir .....                                     | 129            |
| 4.3.2.1                                 | Formulation procedure .....   | 129            |
| 4.3.3                                   | Formulation development of Nanoemulsion of Darunavir .....  | 130            |
| 4.3.3.1                                 | Assessment of solubility of Darunavir in different oils and surfactant ...                            | 130            |
| 4.3.3.2                                 | Formulation of nanoemulsion of Darunavir .....  | 130            |
| 4.3.3.3                                 | Evaluation of nanoemulsion of Darunavir .....   | 131            |
| 4.3.4                                   | Formulation development of peptide grafted solid lipid nanoparticles of Atazanavir sulfate.....       | 132            |
| 4.3.4.1                                 | Formulation of solid lipid nanoparticles of Atazanavir sulfate .....                                  | 132            |
| 4.3.4.2                                 | Grafting of peptide to optimized SLNs of Atazanavir sulfate.....                                      | 134            |
| 4.4                                     | Results and discussion .....  | 134            |
| 4.4.1                                   | Formulation development of Darunavir loaded solid lipid nanoparticles .....                           | 134            |
| 4.4.1.1                                 | Formulation of placebo (without drug) solid lipid nanoparticles.....                                  | 134            |
| 4.4.1.2                                 | Formulation of Darunavir loaded solid lipid nanoparticles.....  | 140            |
| 4.4.2                                   | Formulation development of peptide grafted SLNs of Darunavir .....                                    | 146            |
| 4.4.3                                   | Formulation development of nanoemulsion of Darunavir .....  | 146            |
| 4.4.3.1                                 | Assessment of solubility of Darunavir in various oils and surfactant .....                            | 146            |
| 4.4.3.2                                 | Formulation of nanoemulsion of Darunavir .....  | 147            |
| 4.4.4                                   | Formulation development of peptide grafted Atazanavir sulfate loaded SLNs ..                          | 150            |
| 4.5                                     | References.....   | 154            |
| <b>CHAPTER 5 CHARACTERIZATION .....</b> |   | <b>156-201</b> |
| 5.1                                     | Introduction.....   | 156            |
| 5.2                                     | Materials .....   | 158            |
| 5.3                                     | Characterization of optimized Darunavir loaded SLN formulations.....                                  | 158            |
| 5.3.1                                   | Particle size and zeta potential .....  | 158            |
| 5.3.2                                   | Entrapment efficiency (EE) and drug loading.....  | 158            |
| 5.3.3                                   | Transmission electron microscopy (TEM) and Field emission scanning electron microscopy (FE-SEM) ..... | 159            |
| 5.3.4                                   | Differential scanning calorimetric (DSC) studies .....  | 159            |
| 5.3.5                                   | Fourier transform infrared (FT-IR) spectroscopy .....   | 160            |
| 5.3.6                                   | <i>In-vitro</i> drug release study.....   | 160            |

|         |  |     |
|---------|--|-----|
| 5.3.6.1 | Activation of dialysis membrane.....   | 160 |
| 5.3.6.2 | Preparation of solutions.....  | 160 |
| 5.3.6.3 | Protocol .....   | 161 |
| 5.4     | Characterization of peptide attached solid lipid nanoparticles of Darunavir.....   | 161 |
| 5.4.1   | Particle size and zeta potential .....   | 161 |
| 5.4.2   | Qualitative determination of surface grafted peptide.....  | 162 |
| 5.4.3   | Quantitative determination of bound peptide.....   | 165 |
| 5.4.4   | <i>In-vitro</i> drug release study.....  | 166 |
| 5.5     | Characterization of nanoemulsion of Darunavir.....   | 167 |
| 5.5.1   | Globule size, PDI and Zeta potential.....  | 167 |
| 5.5.2   | Electrical conductivity.....   | 167 |
| 5.5.3   | Drug loading.....  | 167 |
| 5.5.4   | Transmission electron microscopy.....  | 167 |
| 5.5.5   | <i>In-vitro</i> drug release study.....  | 167 |
| 5.6     | Characterization of optimized ATZ loaded solid lipid nanoparticles (ALN-23) and peptide grafted ATZ loaded SLNs (Pept-ATZ-SLN) ..... | 168 |
| 5.6.1   | Particle size and zeta potential .....   | 168 |
| 5.6.2   | EE and drug loading .....  | 168 |
| 5.6.3   | TEM and FE-SEM.....  | 168 |
| 5.6.4   | DSC studies .....  | 169 |
| 5.6.5   | FT-IR spectroscopy .....   | 169 |
| 5.6.6   | Qualitative and quantitative determination of surface grafted peptide .....  | 169 |
| 5.6.7   | <i>In-vitro</i> drug release of Atazanavir loaded solid lipid nanoparticles .....  | 169 |
| 5.7     | Results and discussion .....   | 170 |
| 5.7.1   | Characterization of optimized Darunavir loaded SLN formulations .....  | 170 |
| 5.7.1.1 | Particle size and zeta potential .....   | 170 |
| 5.7.1.2 | EE and drug loading .....  | 173 |
| 5.7.1.3 | TEM and FE-SEM.....  | 173 |
| 5.7.1.4 | DSC studies .....  | 176 |
| 5.7.1.5 | FT-IR spectroscopy .....   | 178 |
| 5.7.1.6 | <i>In-vitro</i> drug release of Darunavir loaded SLNs .....  | 182 |
| 5.7.2   | Characterization of peptide attached solid lipid nanoparticles of Darunavir .....  | 183 |
| 5.7.2.1 | Particle size and zeta potential .....   | 183 |

|  |  |                |
|--|--|----------------|
| 5.7.2.2                                  | Qualitative determination of bound peptide .....   | 184            |
| 5.7.2.3                                  | Quantitative determination of bound peptide .....  | 184            |
| 5.7.2.4                                  | <i>In-vitro</i> drug release study .....   | 186            |
| 5.7.3                                    | Characterization of nanoemulsion of Darunavir .....  | 186            |
| 5.7.3.1                                  | Globule size, PDI and zeta potential .....   | 186            |
| 5.7.3.2                                  | Electrical conductivity .....  | 186            |
| 5.7.3.3                                  | Drug loading .....   | 186            |
| 5.7.3.4                                  | Transmission electron microscopy .....   | 187            |
| 5.7.3.5                                  | <i>In-vitro</i> drug release study .....   | 187            |
| 5.7.4                                    | Characterization of optimized ATZ loaded solid lipid nanoparticles (ALN-23) and peptide grafted ATZ loaded SLNs (Pept-ATZ-SLN) ..... | 190            |
| 5.7.4.1                                  | Particle size and zeta potential .....   | 190            |
| 5.7.4.2                                  | Entrapment efficiency (EE) and drug loading .....  | 191            |
| 5.7.4.3                                  | Transmission electron microscopy (TEM) and Field emission scanning electron microscopy (FE-SEM) .....                                | 191            |
| 5.7.4.4                                  | Differential scanning calorimetric (DSC) studies .....   | 192            |
| 5.7.4.5                                  | Fourier transform infrared (FT-IR) spectroscopy .....  | 193            |
| 5.7.4.6                                  | Qualitative determination of surface grafted peptide .....   | 196            |
| 5.7.4.7                                  | Quantitative determination of surface grafted peptide .....  | 197            |
| 5.7.4.8                                  | <i>In-vitro</i> drug release of Atazanavir loaded solid lipid nanoparticles .....  | 197            |
| 5.8                                      | References .....   | 198            |
| <b>CHAPTER 6 CELL LINE STUDIES .....</b> |  | <b>202-225</b> |
| 6.1                                      | Introduction .....   | 202            |
| 6.2                                      | Materials .....  | 205            |
| 6.3                                      | Subculturing of the cell lines .....   | 206            |
| 6.3.1                                    | Subculturing of Caco-2 cells .....   | 206            |
| 6.3.2                                    | Subculturing of Molt-4 cells .....   | 206            |
| 6.4                                      | Cell counting using haemocytometer .....   | 207            |
| 6.4.1                                    | Haemocytometer .....   | 207            |
| 6.4.2                                    | Preparing cells suspension .....   | 207            |
| 6.4.3                                    | Cell counting .....  | 207            |
| 6.5                                      | Cell cytotoxicity study .....  | 208            |
| 6.5.1                                    | Preparation of phosphate buffer saline pH 7.4 .....  | 208            |

|  |                |
|--|----------------|
| 6.5.2 Preparation MTT solution .....   | 209            |
| 6.5.3 Preparation of stock solutions .....   | 209            |
| 6.5.4 MTT assay protocol.....  | 210            |
| 6.5.4.1 Plating out cells .....  | 210            |
| 6.5.4.2 Addition of formulations .....   | 211            |
| 6.5.4.3 Estimation of surviving cell numbers.....  | 211            |
| 6.5.4.4 Analysis of MTT assay.....   | 211            |
| 6.6 Internalization pathway for SLNs into the Caco-2 cells.....  | 212            |
| 6.6.1 Preparation of 0.5 M NaOH .....  | 212            |
| 6.6.2 Internalization pathway study .....  | 212            |
| 6.6.3 Extraction of drugs from above supernatant .....   | 213            |
| 6.7 Intestinal permeability study.....   | 214            |
| 6.8 Confocal microscopy .....  | 215            |
| 6.8.1 Formulation of coumarin-6 loaded SLNs.....   | 215            |
| 6.8.2 Protocol .....   | 215            |
| 6.9 Results and discussion .....   | 216            |
| 6.9.1 Cell cytotoxicity study.....   | 216            |
| 6.9.2 Internalization pathway for SLNs into the Caco-2 cells .....   | 217            |
| 6.9.3 Intestinal permeability study .....  | 219            |
| 6.9.4 Confocal study.....  | 221            |
| 6.10 References.....   | 223            |
| <b>CHAPTER 7 <i>IN-VIVO</i> STUDIES .....</b>  | <b>226-269</b> |
| 7.1 Introduction.....  | 226            |
| 7.2 Materials .....  | 226            |
| 7.3 Animals.....   | 226            |
| 7.4 Methods.....   | 227            |
| 7.4.1 <i>In-vivo</i> methods of Darunavir loaded solid lipid nanoparticles .....   | 227            |
| 7.4.1.1 Pharmacokinetic profile comparison of three different sized- Darunavir<br>loaded solid lipid nanoparticles ..... | 227            |
| 7.4.1.2 <i>In-situ</i> absorption from stomach and intestine .....   | 228            |
| 7.4.1.3 Lymphatic transport study.....   | 228            |
| 7.4.1.4 Organ biodistribution study.....   | 229            |

|   |                |
|---|----------------|
| 7.4.1.5 Biodistribution of SLNs in Peyer's patch(PP) and Non-peyer's (Non-PP) patch .....                             | 229            |
| 7.4.2 <i>In-vivo</i> methods of optimized Peptide-grafted Darunavir loaded SLNs .....                                 | 230            |
| 7.4.2.1 Pharmacokinetic study .....   | 230            |
| 7.4.2.2 Organ biodistribution study .....   | 231            |
| 7.4.3 <i>In-vivo</i> methods of optimized Darunavir loaded Nanoemulsion .....   | 231            |
| 7.4.3.1 Pharmacokinetic study .....   | 231            |
| 7.4.3.2 Organ biodistribution study .....   | 232            |
| 7.4.4 <i>In-vivo</i> methods of optimized Peptide grafted Atazanavir sulfate loaded SLNs.                             | 232            |
| 7.4.4.1 Pharmacokinetic study .....   | 232            |
| 7.4.4.2 Organ biodistribution study .....   | 233            |
| 7.5 Results and discussion .....  | 234            |
| 7.5.1 <i>In-vivo</i> methods of Darunavir loaded solid lipid nanoparticles .....                                      | 234            |
| 7.5.1.1 Pharmacokinetic profile comparison of three different sized- Darunavir loaded solid lipid nanoparticles ..... | 234            |
| 7.5.1.2 <i>In-situ</i> absorption from stomach and intestine .....  | 237            |
| 7.5.1.3 Lymphatic transport study .....   | 240            |
| 7.5.1.4 Organ biodistribution study .....   | 242            |
| 7.5.1.5 Biodistribution of SLNs in PP and Non-PP patch.....   | 246            |
| 7.5.2 <i>In-vivo</i> methods of optimized Peptide-grafted Darunavir loaded SLNs .....                                 | 249            |
| 7.5.2.1 Pharmacokinetic study .....   | 249            |
| 7.5.2.2 Organ biodistribution study .....   | 251            |
| 7.5.3 <i>In-vivo</i> methods of optimized Darunavir loaded Nanoemulsion.....  | 253            |
| 7.5.3.1 Pharmacokinetic study .....   | 253            |
| 7.5.3.2 Organ biodistribution study .....   | 256            |
| 7.5.4 <i>In-vivo</i> methods of optimized Peptide grafted Atazanavir sulfate loaded SLNs.                             | 261            |
| 7.5.4.1 Pharmacokinetic study .....   | 261            |
| 7.5.4.2 Organ biodistribution study .....   | 263            |
| 7.6 References .....  | 266            |
| <b>CHAPTER 8 STABILITY STUDIES .....</b>  | <b>270-276</b> |
| 8.1 Introduction.....   | 270            |
| 8.2 Methods.....  | 270            |

|   |                |
|---|----------------|
| 8.2.1 Optimized Darunavir loaded solid lipid nanoparticles and peptide grafted<br>Darunavir loaded SLNs ..... | 270            |
| 8.2.2 Optimized Darunavir loaded Nanoemulsion (DNE-3).....  | 271            |
| 8.2.3 Optimized Peptide grafted Atazanavir sulfate loaded SLNs (Pept-ATZ-SLN) ..                              | 271            |
| 8.2.4 Statistical Analysis .....  | 272            |
| 8.3 Results and discussion .....  | 272            |
| 8.3.1 Optimized Darunavir loaded solid lipid nanoparticles and peptide grafted<br>Darunavir loaded SLNs ..... | 272            |
| 8.3.2 Optimized Darunavir loaded nanoemulsion (DNE-3).....  | 274            |
| 8.3.3 Optimized Peptide grafted Atazanavir sulfate loaded SLNs.....   | 275            |
| 8.4 References.....   | 276            |
| <br>  |                |
| <b>CHAPTER 9 SUMMARY AND CONCLUSIONS.....</b>   | <b>277-289</b> |
| 9.1 Summary .....   | 277            |
| 9.2 Conclusions.....  | 289            |